Bengt Hamrén

1.3k total citations · 1 hit paper
41 papers, 958 citations indexed

About

Bengt Hamrén is a scholar working on Endocrinology, Diabetes and Metabolism, Surgery and Molecular Biology. According to data from OpenAlex, Bengt Hamrén has authored 41 papers receiving a total of 958 indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Endocrinology, Diabetes and Metabolism, 12 papers in Surgery and 9 papers in Molecular Biology. Recurrent topics in Bengt Hamrén's work include Diabetes Treatment and Management (17 papers), Diabetes Management and Research (8 papers) and Statistical Methods in Clinical Trials (8 papers). Bengt Hamrén is often cited by papers focused on Diabetes Treatment and Management (17 papers), Diabetes Management and Research (8 papers) and Statistical Methods in Clinical Trials (8 papers). Bengt Hamrén collaborates with scholars based in Sweden, United States and United Kingdom. Bengt Hamrén's co-authors include Ulf G. Eriksson, J. Carl Barrett, Michael Snowden, Stefan Platz, Ruth March, Simon Lennard, Paul Morgan, Steve Rees, Anthony Johnson and Mark J. Anderton and has published in prestigious journals such as SHILAP Revista de lepidopterología, PLoS ONE and Nature Reviews Drug Discovery.

In The Last Decade

Bengt Hamrén

37 papers receiving 928 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Impact of a five-dimensional framework on R&D productivity at AstraZeneca

2018 271 citations Paul Morgan, Dean G. Brown et al. Nature Reviews Drug Discovery profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Bengt Hamrén Sweden	13	301	169	163	152	113	41	958
Jane P. F. Bai United States	25	553 1.8×	236 1.4×	83 0.5×	88 0.6×	136 1.2×	72	1.4k
Mark W. Farmen United States	16	334 1.1×	187 1.1×	96 0.6×	73 0.5×	99 0.9×	26	1.0k
Omri Gottesman United States	19	519 1.7×	119 0.7×	48 0.3×	121 0.8×	122 1.1×	23	1.6k
Akiko Tamon Japan	8	231 0.8×	146 0.9×	37 0.2×	100 0.7×	87 0.8×	12	969
Michael Pacanowski United States	21	249 0.8×	135 0.8×	62 0.4×	190 1.3×	349 3.1×	66	1.3k
Megan Gibbs United States	21	313 1.0×	103 0.6×	70 0.4×	105 0.7×	135 1.2×	46	1.3k
Lisa J. Benincosa United States	14	248 0.8×	92 0.5×	161 1.0×	22 0.1×	80 0.7×	29	804
Jin Y. Jin United States	24	538 1.8×	137 0.8×	210 1.3×	85 0.6×	93 0.8×	95	1.9k
Rosalind Walley United Kingdom	12	555 1.8×	87 0.5×	189 1.2×	32 0.2×	35 0.3×	19	1.1k
Christine Garnett United States	27	1.1k 3.6×	277 1.6×	288 1.8×	51 0.3×	66 0.6×	71	2.6k

Countries citing papers authored by Bengt Hamrén

Since Specialization

Citations

This map shows the geographic impact of Bengt Hamrén's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Bengt Hamrén with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Bengt Hamrén more than expected).

Fields of papers citing papers by Bengt Hamrén

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Bengt Hamrén. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Bengt Hamrén. The network helps show where Bengt Hamrén may publish in the future.

Co-authorship network of co-authors of Bengt Hamrén

This figure shows the co-authorship network connecting the top 25 collaborators of Bengt Hamrén. A scholar is included among the top collaborators of Bengt Hamrén based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Bengt Hamrén. Bengt Hamrén is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Parker, Victoria, Lars Hansen, Darren Robertson, et al.. (2025). Pharmacokinetic‐pharmacodynamic (PK/PD) modelling of cotadutide effect in patients with chronic kidney disease and type 2 diabetes mellitus. British Journal of Clinical Pharmacology. 91(9). 2672–2683.

Ueckert, Sebastian, Lina Zhou, Jenny Cheng, et al.. (2024). Exposure–response modeling for nausea incidence for cotadutide using a Markov modeling approach. CPT Pharmacometrics & Systems Pharmacology. 13(9). 1582–1594. 2 indexed citations

Åstrand, Magnus, et al.. (2024). Population Pharmacokinetic Modeling of Cotadutide: A Dual Agonist Peptide of Glucagon-Like Peptide and Glucagon Receptors Administered to Participants with Type II Diabetes Mellitus, Chronic Kidney Disease, Obesity and Non-Alcoholic Steatohepatitis. Clinical Pharmacokinetics. 63(2). 255–267. 4 indexed citations

Greasley, Peter J., et al.. (2024). Quantifying the integrated physiological effects of endothelin-1 on cardiovascular and renal function in healthy subjects: a mathematical modeling analysis. Frontiers in Pharmacology. 15. 1332394–1332394. 1 indexed citations

Greasley, Peter J., Hiddo J. Lambers Heerspink, Phil Ambery, et al.. (2024). The role of venous capacity in fluid retention with endothelin A antagonism: Mathematical modelling of the RADAR trial. British Journal of Pharmacology. 181(22). 4693–4707. 4 indexed citations

Aoki, Yasunori, Claudia Cabrera, Mario Ouwens, et al.. (2022). Bilirubin levels and kidney function decline: An analysis of clinical trial and real world data. PLoS ONE. 17(6). e0269970–e0269970. 4 indexed citations

Aoki, Yasunori, Bengt Hamrén, Lindsay E. Clegg, et al.. (2021). Assessing reproducibility and utility of clustering of patients with type 2 diabetes and established CV disease (SAVOR -TIMI 53 trial). SHILAP Revista de lepidopterología. 1 indexed citations

Rekić, Dinko, Mats Någård, James Chou, et al.. (2021). Pharmacokinetics of Roxadustat: A Population Analysis of 2855 Dialysis- and Non-Dialysis-Dependent Patients with Chronic Kidney Disease. Clinical Pharmacokinetics. 60(6). 759–773. 12 indexed citations

Wellhagen, Gustaf J., Bengt Hamrén, Maria C. Kjellsson, & Magnus Åstrand. (2020). Dose-Response Mixed Models for Repeated Measures – a New Method for Assessment of Dose-Response. Pharmaceutical Research. 37(8). 157–157. 2 indexed citations

10.

Sokolov, Victor, Gabriel Helmlinger, Catarina Nilsson, et al.. (2019). Comparative quantitative systems pharmacology modeling of anti-PCSK9 therapeutic modalities in hypercholesterolemia. Journal of Lipid Research. 60(9). 1610–1621. 17 indexed citations

11.

Niazi, Mohammad, et al.. (2019). Population Pharmacokinetics/Pharmacodynamics of Ticagrelor in Children with Sickle Cell Disease. Clinical Pharmacokinetics. 58(10). 1295–1307. 10 indexed citations

12.

Mitchell, Pat, Bengt Hamrén, Gabriel Helmlinger, et al.. (2018). Integrating dose estimation into a decision‐making framework for model‐based drug development. Pharmaceutical Statistics. 17(2). 155–168. 1 indexed citations

13.

Morgan, Paul, Dean G. Brown, Simon Lennard, et al.. (2018). Impact of a five-dimensional framework on R&D productivity at AstraZeneca. Nature Reviews Drug Discovery. 17(3). 167–181. 271 indexed citations breakdown →

14.

Cheung, S. Y. Amy, Joanna Parkinson, Corina Dota, et al.. (2018). A tutorial on model informed approaches to cardiovascular safety with focus on cardiac repolarisation. Journal of Pharmacokinetics and Pharmacodynamics. 45(3). 365–381. 5 indexed citations

15.

Aoki, Yasunori, Daniel Röshammar, Bengt Hamrén, & Andrew C. Hooker. (2017). Model selection and averaging of nonlinear mixed-effect models for robust phase III dose selection. Journal of Pharmacokinetics and Pharmacodynamics. 44(6). 581–597. 31 indexed citations

16.

Nyman, Elin, Gabriel Helmlinger, Bengt Hamrén, et al.. (2016). Requirements for multi-level systems pharmacology models to reach end-usage: the case of type 2 diabetes. Interface Focus. 6(2). 20150075–20150075. 19 indexed citations

17.

Macpherson, M., Bengt Hamrén, Marjet J.A.M. Braamskamp, et al.. (2015). Population pharmacokinetics of rosuvastatin in pediatric patients with heterozygous familial hypercholesterolemia. European Journal of Clinical Pharmacology. 72(1). 19–27. 7 indexed citations

18.

Hamrén, Bengt, et al.. (2012). Longitudinal Model-Based Meta-Analysis in Rheumatoid Arthritis: An Application Toward Model-Based Drug Development. Clinical Pharmacology & Therapeutics. 92(3). 352–359. 41 indexed citations

19.

Hamrén, Bengt, Hans Ericsson, Ola Samuelsson, & Mats O. Karlsson. (2008). Mechanistic modelling of tesaglitazar pharmacokinetic data in subjects with various degrees of renal function – evidence of interconversion. British Journal of Clinical Pharmacology. 65(6). 855–863. 11 indexed citations

20.

Burman, Carl‐Fredrik, Bengt Hamrén, & Per Olsson. (2005). Modelling and simulation to improve decision-making in clinical development. Pharmaceutical Statistics. 4(1). 47–58. 16 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact